Last reviewed · How we verify
Standard antiplatelet
Standard antiplatelet is a antiplatelet Small molecule drug developed by Beijing Tiantan Hospital. It is currently in Phase 3 development for Atrial fibrillation for stroke prevention, Acute coronary syndrome, Myocardial infarction. Also known as: Aspirin.
Standard antiplatelet drugs work by inhibiting platelet activation and aggregation, preventing blood clots from forming.
Standard antiplatelet drugs work by inhibiting platelet activation and aggregation, preventing blood clots from forming. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome, Myocardial infarction.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Standard antiplatelet |
|---|---|
| Also known as | Aspirin |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | antiplatelet |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
They do this by blocking the action of platelet activating factors, such as adenosine diphosphate (ADP) and thromboxane A2, which stimulate platelet activation and aggregation. This results in a decrease in the formation of blood clots, which can cause heart attacks and strokes.
Approved indications
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
- Myocardial infarction
Common side effects
- Gastrointestinal bleeding
- Thrombocytopenia
- Hypersensitivity reactions
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA (NA)
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- Anastomotic Leakage Prevention by Endovascular Stenting of the Superior Mesenteric Artery (NA)
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard antiplatelet CI brief — competitive landscape report
- Standard antiplatelet updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI
Frequently asked questions about Standard antiplatelet
What is Standard antiplatelet?
How does Standard antiplatelet work?
What is Standard antiplatelet used for?
Who makes Standard antiplatelet?
Is Standard antiplatelet also known as anything else?
What drug class is Standard antiplatelet in?
What development phase is Standard antiplatelet in?
What are the side effects of Standard antiplatelet?
What does Standard antiplatelet target?
Related
- Drug class: All antiplatelet drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: Beijing Tiantan Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Myocardial infarction
- Also known as: Aspirin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing